AI Challenger
AI is not an assistant — it is a strategic critic. Every challenge explains why.
Challenges assumptions across all 4 AD pipeline assets. Flags contradictions between scenarios. No black box — every challenge is traceable to data, analogs, or benchmarks.
Active Challenges
Your assumption:
KP-723 achieves 7% Rx share at maturity in moderate AD
Your access tightening scenario contradicts this share projection. Oral agents face step therapy barriers in >60% of commercial plans. Historical JAKi launches show payer-driven share erosion of 30-40% vs initial projections.
Your assumption:
NM-26 uptake reaches 9% share with best-in-class itch positioning
This segment is unlikely to be fully owned by dual IL-4Rα/IL-31 MOA. Nemolizumab (pure IL-31Rα) launches 3 years earlier with established itch data. Historical patterns show first-mover advantage in pruritus captures 60% of segment share.
Your assumption:
PX-128 asthma co-indication doubles addressable market by 2033
Consider a sequential label strategy. Tezepire (TSLP mAb) will have 5+ years of asthma data by PX-128 launch. The bispecific advantage over established TSLP monotherapy needs clear superiority data. A phased approach with AD-first, asthma-second may de-risk the portfolio timeline.
Your assumption:
PX-130 cumulative PoS of 14% supports portfolio inclusion
At preclinical stage with 14% PoS, the risk-adjusted NPV of PX-130 is ~$390M vs acquisition cost embedded in the $850M Proteologix deal. If PX-128 succeeds, cannibalization from shared IL-13 target reduces PX-130 incremental value by 35-45%.